Home / Stock ratings / Healthcare Stocks / ABBV
Stock rating · Pharmaceutical Preparations
AbbVie Inc. (ABBV) Stock Rating & Analysis
As of October 7, 2026, MELANY rates AbbVie Inc. 71 out of 100 (Highest Conviction). Its highest factor score is business quality at 100, and its lowest is macro fit at 50.
MELANY ratingRated 2026-10-07ABBV · composite score
About AbbVie Inc.
AbbVie is a pharmaceutical firm with strong exposure to immunology (Humira, Skyrizi, and Rinvoq) and oncology (Imbruvica and Venclexta), spun off from Abbott in early 2013. Its 2020 acquisition of Allergan added products and drugs in aesthetics including Botox, and its 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) further supplement its portfolio.
Rating as of 2026-10-07 · this is a dated snapshot; the live rating is in the app (Pro, free for 30 days). The price above updates in real time.
How ABBV's rating has moved
- +1Past week, since Sep 30: score rose 1 point to 71.
- +2Past four weeks, since Sep 9: score rose 2 points to 71.
Weekly points: Sep 9: 69 · Sep 16: 67 · Sep 23: 68 · Sep 30: 70 · Oct 7: 71 (this page).
From MELANY's own dated rating record. A tier change is reported as a move between named tiers; the score carries the direction.
Why ABBV scores 71/100
ABBV's 8 factor scores run from 50 to 100, and 2 of them sit above its composite of 71. Here is how ABBV breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- Forward P/E 16.4x, earnings growth accelerating
- PEG ratio 0.54 (< 1 = undervalued)
Margins, returns on capital, and balance-sheet strength.
- Gross margin 72%
Direction and relative strength of the recent share-price trend.
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 3 of last 4 quarters
- Earnings in 23 days (strong beat history)
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
- Earnings in 23 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How ABBV compares
As of October 7, 2026, AbbVie Inc. is tied for 4th of 20 in Healthcare Stocks, where the average score is 67.
Key risks for ABBV
- Trading near 52-week high, limited upside without new positive catalyst
Sector and theme context
AbbVie Inc. sits in the Healthcare sector theme, which MELANY currently rates 37/100 for strength. Theme strength feeds ABBV's momentum and catalyst factors above.
ABBV trade plan (Pro)
MELANY has a full position plan for AbbVie Inc.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.
How MELANY rates ABBV
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. AbbVie Inc.'s 71/100 reflects mature factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about ABBV
Is AbbVie Inc. (ABBV) a buy?
As of 2026-10-07, MELANY rated AbbVie Inc. Highest Conviction with a composite score of 71/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is AbbVie Inc.'s MELANY score?
AbbVie Inc. (ABBV) has a MELANY composite score of 71/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the ABBV stock rating calculated?
MELANY scores ABBV from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy AbbVie Inc. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates AbbVie Inc. (ABBV) Highest Conviction with a composite of 71/100 as of 2026-10-07. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the ABBV stock price forecast?
MELANY does not publish price targets or forecasts for ABBV. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 71/100 across eight factors for AbbVie Inc., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is ABBV stock overvalued or undervalued?
MELANY's valuation factor currently reads 53/100 for AbbVie Inc., where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives ABBV's read.
What price should I buy ABBV at?
Rather than chasing the current price, MELANY computes a smart entry zone for ABBV: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.
What are the risks of buying ABBV stock?
The top risks MELANY currently flags for AbbVie Inc.: Trading near 52-week high, limited upside without new positive catalyst. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is AbbVie Inc. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 100/100 for AbbVie Inc., and earnings track record, at 68/100. The 71/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will ABBV stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 71/100 for ABBV right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this ABBV rating?
The rating on this page is a snapshot of MELANY's read as of 2026-10-07. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores ABBV continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, ABBV included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.